Free Trial

PDS Biotechnology (PDSB) Competitors

PDS Biotechnology logo
$0.93 -0.02 (-2.04%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$0.96 +0.03 (+3.10%)
As of 10/17/2025 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PDSB vs. SXTC, MIST, MCRB, CGEN, ELDN, CCCC, THTX, PEPG, MOLN, and NKTX

Should you be buying PDS Biotechnology stock or one of its competitors? The main competitors of PDS Biotechnology include China SXT Pharmaceuticals (SXTC), Milestone Pharmaceuticals (MIST), Seres Therapeutics (MCRB), Compugen (CGEN), Eledon Pharmaceuticals (ELDN), C4 Therapeutics (CCCC), Theratechnologies (THTX), PepGen (PEPG), Molecular Partners (MOLN), and Nkarta (NKTX). These companies are all part of the "pharmaceutical products" industry.

PDS Biotechnology vs. Its Competitors

China SXT Pharmaceuticals (NASDAQ:SXTC) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

China SXT Pharmaceuticals has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Comparatively, PDS Biotechnology has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500.

5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are owned by institutional investors. 4.0% of China SXT Pharmaceuticals shares are owned by company insiders. Comparatively, 9.2% of PDS Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

PDS Biotechnology has a consensus price target of $10.00, suggesting a potential upside of 979.56%. Given PDS Biotechnology's stronger consensus rating and higher possible upside, analysts plainly believe PDS Biotechnology is more favorable than China SXT Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
China SXT Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
PDS Biotechnology
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

In the previous week, China SXT Pharmaceuticals had 1 more articles in the media than PDS Biotechnology. MarketBeat recorded 1 mentions for China SXT Pharmaceuticals and 0 mentions for PDS Biotechnology. China SXT Pharmaceuticals' average media sentiment score of 1.00 beat PDS Biotechnology's score of 0.00 indicating that China SXT Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
China SXT Pharmaceuticals Positive
PDS Biotechnology Neutral

China SXT Pharmaceuticals' return on equity of 0.00% beat PDS Biotechnology's return on equity.

Company Net Margins Return on Equity Return on Assets
China SXT PharmaceuticalsN/A N/A N/A
PDS Biotechnology N/A -184.56%-79.00%

China SXT Pharmaceuticals has higher revenue and earnings than PDS Biotechnology.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China SXT Pharmaceuticals$1.74M95.96-$3.30MN/AN/A
PDS BiotechnologyN/AN/A-$37.61M-$0.92-1.01

Summary

China SXT Pharmaceuticals beats PDS Biotechnology on 7 of the 12 factors compared between the two stocks.

Get PDS Biotechnology News Delivered to You Automatically

Sign up to receive the latest news and ratings for PDSB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PDSB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PDSB vs. The Competition

MetricPDS BiotechnologyMED IndustryMedical SectorNASDAQ Exchange
Market Cap$43.56M$3.44B$6.19B$10.55B
Dividend YieldN/A2.28%5.70%4.81%
P/E Ratio-1.0123.0185.5427.13
Price / SalesN/A486.53611.78133.04
Price / CashN/A46.9237.1060.81
Price / Book1.8210.4112.236.52
Net Income-$37.61M-$52.77M$3.33B$276.93M
7 Day Performance-2.22%2.31%1.17%1.93%
1 Month Performance-11.78%12.59%6.85%2.19%
1 Year Performance-71.50%11.18%58.93%34.62%

PDS Biotechnology Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PDSB
PDS Biotechnology
1.2163 of 5 stars
$0.93
-2.0%
$10.00
+979.6%
-71.5%$43.56MN/A-1.0120
SXTC
China SXT Pharmaceuticals
1.0778 of 5 stars
$1.45
-1.9%
N/A-71.5%$171.49M$1.74M0.0090Positive News
Short Interest ↓
MIST
Milestone Pharmaceuticals
2.1545 of 5 stars
$1.99
flat
$4.50
+126.1%
+30.2%$169.14M$1M-2.3730
MCRB
Seres Therapeutics
2.3938 of 5 stars
$19.23
+0.6%
$14.33
-25.5%
+11.6%$167.39M$126.32M-4.18330
CGEN
Compugen
1.6527 of 5 stars
$2.24
+21.1%
$4.00
+78.6%
+9.6%$165.09M$27.86M-10.1870News Coverage
Gap Up
High Trading Volume
ELDN
Eledon Pharmaceuticals
1.8091 of 5 stars
$2.72
-0.7%
$10.00
+267.6%
+15.8%$164.08MN/A-2.3210News Coverage
Gap Up
CCCC
C4 Therapeutics
3.5467 of 5 stars
$2.11
-6.2%
$8.50
+302.8%
-62.7%$160.13M$35.58M-1.34150News Coverage
THTX
Theratechnologies
N/A$3.42
+0.9%
N/A+157.1%$157.21M$84.38M-17.99140High Trading Volume
PEPG
PepGen
3.0095 of 5 stars
$4.55
-3.6%
$8.40
+84.6%
-45.3%$154.65MN/A-1.5430Short Interest ↑
MOLN
Molecular Partners
1.4854 of 5 stars
$3.87
+1.7%
$8.00
+107.0%
-22.1%$153.42M$5.65M-1.86180Analyst Forecast
Gap Down
NKTX
Nkarta
2.4538 of 5 stars
$2.26
+4.6%
$13.50
+497.3%
-46.0%$153.41MN/A-1.53140

Related Companies and Tools


This page (NASDAQ:PDSB) was last updated on 10/19/2025 by MarketBeat.com Staff
From Our Partners